Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose-Reference-Cited by-同舟云学术

Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose

Published:2020-01-01 Issue:1 Volume:24 Page:65-72
ISSN:1027-3719
Container-title:The International Journal of Tuberculosis and Lung Disease
language:en
Short-container-title:int j tuberc lung dis

Author:

Hong H.¹,Dowdy D. W.²,Dooley K. E.³,Francis H. W.⁴,Budhathoki C.⁵,Han H-R.⁶,Farley J. E.¹

Affiliation:

1. Johns Hopkins University School of Nursing, Baltimore, MD, The REACH Initiative, Johns Hopkins University School of Nursing, Baltimore, MD

2. Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

3. Divisions of Clinical Pharmacology and Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, MD

4. Division of Head and Neck Surgery and Communication Sciences, Duke University School of Medicine, Durham, NC

5. Johns Hopkins University School of Nursing, Baltimore, MD

6. Johns Hopkins University School of Nursing, Baltimore, MD, Center for Cardiovascular and Chronic Care, Johns Hopkins University, Baltimore, MD, USA

Abstract

SETTING: The ototoxic effects of aminoglycosides (AGs) lead to permanent hearing loss, which is one of the devastating consequences of multidrug-resistant tuberculosis (MDR-TB) treatment. As AG ototoxicity is dose-dependent, the impact of a surrogate measure of AG exposure on AG-induced hearing loss warrants close attention for settings with limited therapeutic drug monitoring.OBJECTIVE: To explore the prognostic impact of cumulative AG dose on AG ototoxicity in patients following initiation of AG-containing treatment for MDR-TB.DESIGN: This prospective cohort study was nested within an ongoing cluster-randomized trial of nurse case management intervention across 10 MDR-TB hospitals in South Africa.RESULTS: The adjusted hazard of AG regimen modification due to ototoxicity in the high-dose group (≥75 mg/kg/week) was 1.33 times higher than in the low-dose group (<75 mg/kg/week, 95%CI 1.09–1.64). The adjusted hazard of developing audiometric hearing loss was 1.34 times higher than in the low-dose group (95%CI 1.01–1.77). Pre-existing hearing loss (adjusted hazard ratio [aHR] 1.71, 95%CI 1.29–2.26) and age (aHR 1.16 per 10 years of age, 95%CI 1.01–1.33) were also associated with an increased risk of hearing loss.CONCLUSION: MDR-TB patients with high AG dose, advanced age and pre-existing hearing loss have a significantly higher risk of AG-induced hearing loss. Those at high risk may be candidates for more frequent monitoring or AG-sparing regimens.

Publisher

International Union Against Tuberculosis and Lung Disease

Subject

Infectious Diseases,Pulmonary and Respiratory Medicine

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy;JAMA Oncology;2024-07-01

2. Re-telling the story of aminoglycoside ototoxicity: tales from sub-Saharan Africa;Frontiers in Neurology;2024-06-28

3. Hearing Loss Detection and Early Intervention Strategies in Kenya;Annals of Global Health;2024

4. Hearing assessment and treatment outcome in ENT tuberculosis at a tertiary hospital in India;The Egyptian Journal of Otolaryngology;2023-10-06

5. Protocol for a systematic review of long-term physical sequelae and financial burden of multidrug-resistant and extensively drug-resistant tuberculosis;PLOS ONE;2023-05-15